125 related articles for article (PubMed ID: 37930123)
21. A cost-effectiveness analysis of trametinib plus dabrafenib as first-line therapy for metastatic BRAF V600-mutated melanoma in the Swiss setting.
Matter-Walstra K; Braun R; Kolb C; Ademi Z; Dummer R; Pestalozzi BC; Schwenkglenks M
Br J Dermatol; 2015 Dec; 173(6):1462-70. PubMed ID: 26332527
[TBL] [Abstract][Full Text] [Related]
22. Spartalizumab or placebo in combination with dabrafenib and trametinib in patients with
Tawbi HA; Robert C; Brase JC; Gusenleitner D; Gasal E; Garrett J; Savchenko A; Görgün G; Flaherty KT; Ribas A; Dummer R; Schadendorf D; Long GV; Nathan PD; Ascierto PA
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35728875
[TBL] [Abstract][Full Text] [Related]
23. Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i.
Dummer R; Lebbé C; Atkinson V; Mandalà M; Nathan PD; Arance A; Richtig E; Yamazaki N; Robert C; Schadendorf D; Tawbi HA; Ascierto PA; Ribas A; Flaherty KT; Pakhle N; Campbell CD; Gusenleitner D; Masood A; Brase JC; Gasal E; Long GV
Nat Med; 2020 Oct; 26(10):1557-1563. PubMed ID: 33020648
[TBL] [Abstract][Full Text] [Related]
24. Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB-C, BRAF
Long GV; Saw RPM; Lo S; Nieweg OE; Shannon KF; Gonzalez M; Guminski A; Lee JH; Lee H; Ferguson PM; Rawson RV; Wilmott JS; Thompson JF; Kefford RF; Ch'ng S; Stretch JR; Emmett L; Kapoor R; Rizos H; Spillane AJ; Scolyer RA; Menzies AM
Lancet Oncol; 2019 Jul; 20(7):961-971. PubMed ID: 31171444
[TBL] [Abstract][Full Text] [Related]
25. Interim analysis for post-marketing surveillance of dabrafenib and trametinib combination therapy in Japanese patients with unresectable and metastatic melanoma with BRAF V600 mutation.
Teshima Y; Kizaki M; Kurihara R; Kano R; Harumiya M
Int J Clin Oncol; 2020 Oct; 25(10):1870-1878. PubMed ID: 32699976
[TBL] [Abstract][Full Text] [Related]
26. Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor.
Johnson DB; Flaherty KT; Weber JS; Infante JR; Kim KB; Kefford RF; Hamid O; Schuchter L; Cebon J; Sharfman WH; McWilliams RR; Sznol M; Lawrence DP; Gibney GT; Burris HA; Falchook GS; Algazi A; Lewis K; Long GV; Patel K; Ibrahim N; Sun P; Little S; Cunningham E; Sosman JA; Daud A; Gonzalez R
J Clin Oncol; 2014 Nov; 32(33):3697-704. PubMed ID: 25287827
[TBL] [Abstract][Full Text] [Related]
27. Improved overall survival in melanoma with combined dabrafenib and trametinib.
Robert C; Karaszewska B; Schachter J; Rutkowski P; Mackiewicz A; Stroiakovski D; Lichinitser M; Dummer R; Grange F; Mortier L; Chiarion-Sileni V; Drucis K; Krajsova I; Hauschild A; Lorigan P; Wolter P; Long GV; Flaherty K; Nathan P; Ribas A; Martin AM; Sun P; Crist W; Legos J; Rubin SD; Little SM; Schadendorf D
N Engl J Med; 2015 Jan; 372(1):30-9. PubMed ID: 25399551
[TBL] [Abstract][Full Text] [Related]
28. A randomised phase 2 study of intermittent versus continuous dosing of dabrafenib plus trametinib in patients with BRAF
Dayimu A; Gupta A; Matin RN; Nobes J; Board R; Payne M; Rao A; Fusi A; Danson S; Eccles B; Carser J; Brown CO; Steven N; Bhattacharyya M; Brown E; Gonzalez M; Highley M; Pickering L; Kumar S; Waterston A; Burghel G; Demain L; Baker E; Wulff J; Qian W; Twelves S; Middleton M; Corrie P
Eur J Cancer; 2024 Jan; 196():113455. PubMed ID: 38029480
[TBL] [Abstract][Full Text] [Related]
29. Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial.
Amaria RN; Prieto PA; Tetzlaff MT; Reuben A; Andrews MC; Ross MI; Glitza IC; Cormier J; Hwu WJ; Tawbi HA; Patel SP; Lee JE; Gershenwald JE; Spencer CN; Gopalakrishnan V; Bassett R; Simpson L; Mouton R; Hudgens CW; Zhao L; Zhu H; Cooper ZA; Wani K; Lazar A; Hwu P; Diab A; Wong MK; McQuade JL; Royal R; Lucci A; Burton EM; Reddy S; Sharma P; Allison J; Futreal PA; Woodman SE; Davies MA; Wargo JA
Lancet Oncol; 2018 Feb; 19(2):181-193. PubMed ID: 29361468
[TBL] [Abstract][Full Text] [Related]
30. Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma.
Schadendorf D; Amonkar MM; Stroyakovskiy D; Levchenko E; Gogas H; de Braud F; Grob JJ; Bondarenko I; Garbe C; Lebbe C; Larkin J; Chiarion-Sileni V; Millward M; Arance A; Mandalà M; Flaherty KT; Nathan P; Ribas A; Robert C; Casey M; DeMarini DJ; Irani JG; Aktan G; Long GV
Eur J Cancer; 2015 May; 51(7):833-40. PubMed ID: 25794603
[TBL] [Abstract][Full Text] [Related]
31. Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer.
Corcoran RB; Atreya CE; Falchook GS; Kwak EL; Ryan DP; Bendell JC; Hamid O; Messersmith WA; Daud A; Kurzrock R; Pierobon M; Sun P; Cunningham E; Little S; Orford K; Motwani M; Bai Y; Patel K; Venook AP; Kopetz S
J Clin Oncol; 2015 Dec; 33(34):4023-31. PubMed ID: 26392102
[TBL] [Abstract][Full Text] [Related]
32. Safety, tolerability, and pharmacokinetic profile of dabrafenib in Japanese patients with BRAF
Fujiwara Y; Yamazaki N; Kiyohara Y; Yoshikawa S; Yamamoto N; Tsutsumida A; Nokihara H; Namikawa K; Mukaiyama A; Zhang F; Tamura T
Invest New Drugs; 2018 Apr; 36(2):259-268. PubMed ID: 28879519
[TBL] [Abstract][Full Text] [Related]
33. Tolerance and efficacy of BRAF plus MEK inhibition in patients with melanoma who previously have received programmed cell death protein 1-based therapy.
Saab KR; Mooradian MJ; Wang DY; Chon J; Xia CY; Bialczak A; Abbate KT; Menzies AM; Johnson DB; Sullivan RJ; Shoushtari AN
Cancer; 2019 Mar; 125(6):884-891. PubMed ID: 30521084
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and Safety of Trametinib in Non-V600 BRAF Mutant Melanoma: A Phase II Study.
Nebhan CA; Johnson DB; Sullivan RJ; Amaria RN; Flaherty KT; Sosman JA; Davies MA
Oncologist; 2021 Sep; 26(9):731-e1498. PubMed ID: 33861486
[TBL] [Abstract][Full Text] [Related]
35. Efficacy, safety and factors associated with disease progression in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: An open label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib.
Saiag P; Robert C; Grob JJ; Mortier L; Dereure O; Lebbe C; Mansard S; Grange F; Neidhardt EM; Lesimple T; Machet L; Bedane C; Maillard H; Dalac-Rat S; Nardin C; Szenik A; Denden A; Dutriaux C
Eur J Cancer; 2021 Sep; 154():57-65. PubMed ID: 34243078
[TBL] [Abstract][Full Text] [Related]
36. Future of combination therapy with dabrafenib and trametinib in metastatic melanoma.
Zia Y; Chen L; Daud A
Expert Opin Pharmacother; 2015; 16(14):2257-63. PubMed ID: 26331795
[TBL] [Abstract][Full Text] [Related]
37. Clinical and radiological response of BRAF inhibition and MEK inhibition in patients with brain metastases from BRAF-mutated melanoma.
Geukes Foppen MH; Boogerd W; Blank CU; van Thienen JV; Haanen JB; Brandsma D
Melanoma Res; 2018 Apr; 28(2):126-133. PubMed ID: 29356790
[TBL] [Abstract][Full Text] [Related]
38. Nivolumab (OPDIVOO) BRAF V600 mutation-negative metastatic or inoperable melanoma: survival advantage.
Prescrire Int; 2016 Dec; 25(177):289-292. PubMed ID: 30758924
[TBL] [Abstract][Full Text] [Related]
39. Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma.
Ribas A; Lawrence D; Atkinson V; Agarwal S; Miller WH; Carlino MS; Fisher R; Long GV; Hodi FS; Tsoi J; Grasso CS; Mookerjee B; Zhao Q; Ghori R; Moreno BH; Ibrahim N; Hamid O
Nat Med; 2019 Jun; 25(6):936-940. PubMed ID: 31171879
[TBL] [Abstract][Full Text] [Related]
40. Patient-reported outcomes in patients with resected, high-risk melanoma with BRAF
Schadendorf D; Hauschild A; Santinami M; Atkinson V; Mandalà M; Chiarion-Sileni V; Larkin J; Nyakas M; Dutriaux C; Haydon A; Robert C; Mortier L; Lesimple T; Plummer R; Schachter J; Dasgupta K; Manson S; Koruth R; Mookerjee B; Kefford R; Dummer R; Kirkwood JM; Long GV
Lancet Oncol; 2019 May; 20(5):701-710. PubMed ID: 30928620
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
